Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
4.000
+0.360 (+9.89%)
Delayed Quote
Updated: 2:24 PM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
27
28
Next >
Lexaria Celebrates its 70th Patent Award
October 28, 2026
New patents awarded in the US, Canada, and Europe IP protection for treatments for Epilepsy, Diabetes, and Hypertension
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
October 21, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Announces Results from Animal Study GLP-1-A26-1
October 15, 2026
Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Announces Results From Animal Study GLP-1-A26-1
October 15, 2026
Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD
Via
TheNewswire.com
Topics
Intellectual Property
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
October 06, 2026
Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034 Novo announces additional weight-loss in patients switching from injected to oral delivery
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Updates Financial Position
September 17, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
September 09, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Announces Closing of Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds
September 09, 2026
Kelowna, British Columbia – September 9, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today closed its...
Via
TheNewswire.com
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
September 08, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 04, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Receives USD$2.6 Million Tax Rebate Payment
September 01, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Receives USD$2.6 Million Tax Rebate Payment
September 01, 2026
Lexaria’s 2025 Australian human study results in a USD$2.6 million cash rebate
Via
TheNewswire.com
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
August 24, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Enters a Material Transfer Agreement With PegBio
August 13, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Announces Effective Date for Reverse Stock Split
July 30, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Updates Business Development
July 06, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
June 25, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
June 23, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
June 17, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
June 09, 2026
Via
ACCESS Newswire
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
June 03, 2026
Via
ACCESS Newswire
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
May 19, 2026
Via
ACCESS Newswire
Lexaria Bioscience Releases Second Episode of Investor Video Series
May 07, 2026
Via
ACCESS Newswire
Lexaria Updates Progress on Human Study #7
May 05, 2026
Via
ACCESS Newswire
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
May 01, 2026
Via
ACCESS Newswire
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
April 29, 2026
Via
ACCESS Newswire
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
April 23, 2026
Via
ACCESS Newswire
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
April 21, 2026
Via
ACCESS Newswire
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
April 15, 2026
Via
ACCESS Newswire
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
April 07, 2026
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
27
28
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
